ELUT Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -11.53% compared to Elutia, Inc.'s net margin of -12425.36%. Elutia, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Elutia, Inc. has a consensus price target of $4.00, signalling upside risk potential of 615.31%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Elutia, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Elutia, Inc. is more attractive than Perspective Therapeutics, Inc..

Elutia, Inc. has a beta of 0.630, which suggesting that the stock is 37.049% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Elutia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elutia, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Elutia, Inc. quarterly revenues are $3.3M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Elutia, Inc.'s net income of -$383K is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Elutia, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elutia, Inc. is 1.13x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex, Inc. has a net margin of -11.53% compared to Elutia, Inc.'s net margin of -44.78%. Elutia, Inc.'s return on equity of -- beat Teleflex, Inc.'s return on equity of -7.84%.

Elutia, Inc. has a consensus price target of $4.00, signalling upside risk potential of 615.31%. On the other hand Teleflex, Inc. has an analysts' consensus of $132.00 which suggests that it could grow by 7.91%. Given that Elutia, Inc. has higher upside potential than Teleflex, Inc., analysts believe Elutia, Inc. is more attractive than Teleflex, Inc..

Elutia, Inc. has a beta of 0.630, which suggesting that the stock is 37.049% less volatile than S&P 500. In comparison Teleflex, Inc. has a beta of 0.954, suggesting its less volatile than the S&P 500 by 4.59%.

Elutia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex, Inc. offers a yield of 1.11% to investors and pays a quarterly dividend of $0.34 per share. Elutia, Inc. pays -- of its earnings as a dividend. Teleflex, Inc. pays out 91.92% of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elutia, Inc. quarterly revenues are $3.3M, which are smaller than Teleflex, Inc. quarterly revenues of $913M. Elutia, Inc.'s net income of -$383K is higher than Teleflex, Inc.'s net income of -$408.9M. Notably, Elutia, Inc.'s price-to-earnings ratio is -- while Teleflex, Inc.'s PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elutia, Inc. is 1.13x versus 1.73x for Teleflex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -11.53% compared to Elutia, Inc.'s net margin of -862.39%. Elutia, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.

Elutia, Inc. has a consensus price target of $4.00, signalling upside risk potential of 615.31%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than Elutia, Inc., analysts believe VolitionRX Ltd. is more attractive than Elutia, Inc..

Elutia, Inc. has a beta of 0.630, which suggesting that the stock is 37.049% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Elutia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elutia, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Elutia, Inc. quarterly revenues are $3.3M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Elutia, Inc.'s net income of -$383K is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Elutia, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elutia, Inc. is 1.13x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -11.53% compared to Elutia, Inc.'s net margin of 3.93%. Elutia, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Elutia, Inc. has a consensus price target of $4.00, signalling upside risk potential of 615.31%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Elutia, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Elutia, Inc. is more attractive than Xtant Medical Holdings, Inc..

Elutia, Inc. has a beta of 0.630, which suggesting that the stock is 37.049% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Elutia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elutia, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Elutia, Inc. quarterly revenues are $3.3M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Elutia, Inc.'s net income of -$383K is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Elutia, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elutia, Inc. is 1.13x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.